Evidence map›Paper›PMID 37620430›Full record

ArticleJournal of cancer research and clinical oncology2023

Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response.

Yue Jiang, Yingquan Ye, Yi Huang, Yue Wu, Gaoxiang Wang, Zhongxuan Gui, Mengmeng Zhang, Mei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yue Jiang *Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yingquan Ye *Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yi Huang *Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yue WuOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Gaoxiang WangOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Zhongxuan GuiOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Mengmeng ZhangOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Mei ZhangOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China. zhangmei@ahmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo provide more precise treatment options for pancreatic adenocarcinoma (PAAD) patients and improve their prognosis,we established a novel anoikis-related long non-coding RNA signature (ARLSig) to predict the prognosis and immune response for PAAD patients.

methodsWe downloaded information on PAAD from The Cancer Genome Atlas (TCGA) database, and screened long non-coding RNA (lncRNA) linked with anoikis, and prognostic signatures with these lncRNAs. After that, ARLSig was verified using receiver operating characteristic (ROC) and C-index curves. To further investigate the role of ARLSig, we also performed enrichment analyses using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO). Additionally, using immunological correlation analysis and single-sample genetic enrichment analysis, we investigated the effectiveness of PAAD immunotherapy.

resultsWe screened 7 lncRNAs to construct a novel ARLSig and utilized it to predict the efficacy of immunotherapy and the prognosis of PAAD patients.

conclusionARLSig can identify patients who will benefit from immunotherapy and improve the prediction of PAAD patient prognosis.

Indexed as

AdenocarcinomaPancreatic NeoplasmsRNA, Long NoncodingAnoikisHumansImmunityPrognosisRNA, Long NoncodingImmunotherapyNomogramPAADPrognosis

Identifiers

PMID37620430
PMCPMC11797502

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.